• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » MDS Pharma Services to Expand Early-Stage Operations in Taiwan

MDS Pharma Services to Expand Early-Stage Operations in Taiwan

June 11, 2009
CenterWatch Staff

MDS Pharma Services, the CRO division of MDS, is undertaking a major renovation and expansion of its discovery operation in Taiwan as part of the company's recently announced plan to focus on early-stage clinical research.

MDS is doubling its capacity for in vivo safety and efficacy testing and improve its molecular screening and profiling capabilities at the Taiwan site. The project will be completed in 2010.

The Taiwan facility is part of MDS Pharma Services' Pharmacology/DMPK  service line, which offers molecular, cellular, ADME/DMPK and in vivo assays for drug development. The Taiwan site offers capabilities in molecular and cellular pharmacology, including more than 800 assays, multiple assay methodologies, high-throughput screening with robotic automation, and expert assay development.

"This new and expanded facility will cement our position as the global leader in the discovery pharmacology space, where we are one of the top two providers of molecular screening, and a key supplied of in vivo efficacy and safety testing," said MDS Pharma Services president David Spaight in a company statement.

MDS recently entered into deal with INC Research to sell off MDS Pharma's phase II through IV contract research business for $50 million. As part of that acquisition (expected to close in July), MDS announced that it would focus its Pharma Services unit on discovery through phase IIa proof-of-concept services.
 

Upcoming Events

  • 15Apr

    Five Telltale Signs You’re Ready for an Electronic TMF System

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

  • 06May

    The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Clinical-Trial-Brainstorming

    FDA, Industry Tackle Problem of Including Older Adults in Trials

  • ClinicalTrialNetwork-360x240.png

    National Community-Based Research Network Would Improve Reach of Trials

  • Bottleneck-360x240.png

    Sites Face Trials Bottleneck After Pandemic, But Also Opportunities

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Genetic Research and IBC Oversight Requirements

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing